Azelastine protects against CA1 traumatic neuronal injury in the hippocampal slice

European Journal of Pharmacology

Volumn 300, Issue 1-2, 1996, Pages 43-49

  Girard, Joanna ^a   Panizzon, Kimberly ^a   Wallis, Roi Ann ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Azelastine; Hippocampus; In vitro; Leukotriene; NMDA (N methyl D aspartate); Traumatic brain injury

Indexed keywords

3 [3 TERT BUTYLTHIO 1 (4 CHLOROBENZYL) 5 ISOPROPYL 2 INDOLYL] 2,2 DIMETHYLPROPIONIC ACID; ANTIALLERGIC AGENT; AZELASTINE; LEUKOTRIENE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; VERLUKAST;

ANIMAL MODEL; ANIMAL TISSUE; ANTIDROMIC STIMULATION; ARTICLE; BRAIN INJURY; BRAIN SLICE; CONTROLLED STUDY; HIPPOCAMPUS; MALE; NERVE CELL LESION; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RAT; SPIKE;

EID: 0029873410     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/0014-2999(95)00804-7     Document Type: Article

References (29)

1. Achterrath-Tuckermann, U., T. Simmet, W. Luck, I. Szelenyi and B.A. Peskar, 1988, Inhibition of cysteinyl-leukotriene production by azelastine and its biological significance, Agents Actions 24, 217.
2. 2 activities in the serum and cerebrospinal fluid during acute cerebral ischemia, Prostagl. Leukotr. Essent. Fatty Acids 43, 247.
3. 2 levels following differing ischemic periods in rat brain tissue, Prostagl. Leukotr. Essent. Fatty Acids 42, 67.
4. Auer, R.N., M.L. Jenson and I.Q. Wishaw, 1989, Neurobehavioral deficit due to ischemic brain damage limited to half of the CA1 section of the hippocampus, J. Neurosci. 9, 1641.
5. 4 selectively increases blood-brain barrier permeability after focal ischemia in rats, J. Cereb. Blood Flow Metab. 11, 638.
6. Black, K.L. and J.T. Hoff, 1985, Leukotrienes increase blood-brain barrier permeability following intraparenchymal injections in rats, Ann. Neurol. 18, 349.
7. Bliss, T.V.P. and G.L. Collingridge, 1993, A synaptic model of memory: long-term potentiation in the hippocampus, Nature 361, 31.
8. Bullock, R. and H. Fujisawa, 1982, The role of glutamate antagonists for the treatment of CNS injury, J. Neurotrauma 9, Suppl. 2, S443.
9. Casale, T.B., 1989, the interaction of azelastine with human lung histamine H1, beta, and muscarinic receptor-binding sites, J. Allergy Clin. Immunol. 83, 771.
10. Collingridge, G.L., 1992, The mechanisms of induction of NMDA receptor-dependent long-term potentiation in the hippocampus, Exp. Physiol. 77, 771.
11. Dummuis, A., M. Sebben, L. Haynes, J.P. Pin and J. Bockart, 1988, NMDA receptors activate the arachidonic acid cascade system in striatal neurons, Nature 336, 68.
12. Faden, A.I., P. Demediuk, S.S. Panter and R. Vink, 1989, The role of excitatory amino acids and NMDA receptors in traumatic brain injury, Science 244, 798.
13. Gronwall, D. and P, Wrightson, 1974, Delayed recovery of intellectual function after minor head injury, Lancet 2, 605.
14. Kiwak, J.J., M.A. Moskowitz and L. Levine, 1985, Leukotriene production in gerbil brain after ischemic insult, subarachnoid hemorrhage, and concussive injury, J. Neurosurg. 62, 865.
15. Lewis, R.A., K.F. Austen and R.J. Soberman, 1990, Leukotrienes and other products of the 5-lipoxygenase pathway, New Engl. J. Med. 10, 645.
16. Miyazaki, S., Y. Katayama, B.C. Lyeth, L.W. Jenkins et al., 1992, Enduring suppression of hippocampal long-term potentiation following traumatic brain injury in rat, Brain Res. 585, 335.
17. 4 in gerbil brains after ischemia and reperfusion, Science 224, 886.
18. Nishihira, J., T. Hayakawa, K. Suzuki, K.L. Katao and T. Ishibashi, 1989, Effect of azelastine on leukotriene synthesis in murine peritoneal cells and on thromboxane synthesis in human platelets, Int. Arch. Allergy Appl. Immunol. 90, 285.
19. Pellerin, L. and L.S. Wolfe, 1991, Release of Arachidonic Acid by NMDA-Receptor Activation in the Rat Hippocampus, Neurochem. Res. 16, 983.
20. Rimel, R.W., B. Giordani, J.T. Earth and J.A. Jane, 1982, Moderate head injury: completing the clinical spectrum of brain injury, Neurosurgery 11, 344.
21. Schmidt-Kastner, R. and T.F, Freund, 1991, Selective vulnerability in brain ischemia, Neuroscience 40, 599.
22. Schurr, A., K. Reid, M.T. Tseng, H.L. Edmonds, 1984, The stability of the hippocampal slice preparation, an electrophysiological and ultrastructural analysis, Brain Res. 297, 357.
23. Umeki, S., 1992, Effects of anti-allergic drugs on human neutrophil superoxide-generating NADPH oxidase, Biochem. Pharmacol. 43, 1109.
24. Wallis, R.A. and K.L. Panizzon, 1993, Protection from hypoxic and N-methyl-D-aspartate injury with azelastine, a leukotriene inhibitor, Eur. J. Pharmacol. 238, 165.
25. Wallis, R.A., K.L. Panizzon and E.G. Wasterlain, 1992, Protective effects of felbamate against hypoxia in the rat hippocampal slice, Stroke 23, 546.
26. Williams, J.H. and T.V.P. Bliss, 1989, An in vitro study of the effect of lipoxygenase and cyclo-oxygenase inhibitors of arachidonic acid on the induction and maintenance of long-term potentiation in the hip-pocampus, Neurosci. Lett. 107, 301.
27. Yavin, E., B. Kunievsky, N.G. Bazan and S. Havel, 1992, Regulation of arachidonic acid metabolism in (he perinatal brain during development and under ischemic stress, Adv. Exp. Med. Biol. 318, 314.
28. Young, R.N., 1991, Development of novel leukotriene-based anti-asthma drugs; MK-886 and MK-571, Agents Actions 34, Suppl., 179.
29. Zechel, H.J., N. Brock, D. Lenke and U. Achterrath-Tuckermann, 1981, Pharmacological and toxicological properties of azelastine, a novel antiallergic agent, Arzneim.-Forsch. 31, 1184.